Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06194825 | EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy | PHASE3 | ACTIVE NOT_RECRUITING | 64 | — | — | Dec 1, 2023 | Jan 5, 2027 | Apr 27, 2026 | 26 | China |
To evaluate the effect of eplontersen compared to placebo on serum transthyretin (TTR) concentration up to 24 weeks
| Arm | Type | Description |
|---|---|---|
| Eplontersen | EXPERIMENTAL | Eplontersen by subcutaneous injection once every 4 weeks |
| placebo | PLACEBO_COMPARATOR | Eplontersen-matching placebo by subcutaneous injection once every 4 weeks |
| Name | Type | Description |
|---|---|---|
| Eplontersen | DRUG | Eplontersen by subcutaneous injection |
| Placebo | DRUG | Eplontersen-matching placebo by subcutaneous injection |
Inclusion Criteria: 1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements. 2. 20 to 90 years of age (inclusive). 3. Females: must be non-pregnant and non-lactating and either: 1. surgically s...